


**Nestor Healthcare Group Limited**

**Directors' report and financial statements**

Year ended 31st January 2013  
Registered number 1992981

TUESDAY



\*A2E6KU4B\*

A42

06/08/2013

#168

COMPANIES HOUSE

## **Directors' report and financial statements**

### **Contents**

Directors' report	2
Directors' responsibilities statement	4
Independent auditors' report to the shareholders of Nestor Healthcare Group Limited	5
Profit and loss account	7
Statement of total recognised gains and losses	8
Reconciliation of movements in shareholder's funds	8
Balance sheet	9
Notes to the financial statements	10

## Directors' report

The directors are pleased to present their annual report and the audited financial statements for the year ended 31st January 2013. Comparative figures are presented for the 13 month period ended 31<sup>st</sup> January 2012.

### Basis of preparation

The results have been prepared in accordance with UK Generally Accepted Accounting Principles ("UK GAAP"), consistent with preparation of the financial statements of Acromas Holdings Limited which has been the Company's ultimate holding company since 1<sup>st</sup> February 2011.

The accounting reference date of the Company has been changed from 31<sup>st</sup> December to 31<sup>st</sup> January in the year ended 31<sup>st</sup> January 2012, therefore comparative figures for the prior year in these financial statements are presented for 13 months to 31<sup>st</sup> January 2012.

### Principal activities, business review and future developments

Nestor Healthcare Group Limited ("the Company") is an intermediate holding company for companies within the healthcare division of the Acromas group of companies, whose principal activities are the provision of services to the healthcare and homecare markets. The Company does not trade in its own right and there are currently no plans to change this.

The ultimate holding company of the Company remains Acromas Holdings Limited.

### Results and dividends

The loss attributable to shareholders disclosed in the profit and loss account was £(91,000) (2012: loss of £(3,545,000)). No dividend has been declared or paid (2012: a dividend of £2,824,000 was paid to shareholders in January 2011 having been approved by directors on 3<sup>rd</sup> December 2010).

### Directors

M A Ellis and S M Howard served as directors throughout the period.

J Ivers resigned as a director on 26<sup>th</sup> July 2012.

Other directors were appointed as follows –

PJV Dixon appointed 3<sup>rd</sup> September 2012  
M B Jackson appointed 3<sup>rd</sup> September 2012  
T M Pethick appointed 3<sup>rd</sup> September 2012

### Directors' interests

The interests of directors in the share capital of the Company were as shown in the table below.

	Ordinary shares		SAYE Scheme	
	31 01 13	31 01 12	31 01 13	31 01 12
M Ellis	-	-	20,814	20,814
J Ivers	-	-	-	46,399
S Howard	-	-	-	-
P Dixon	-	-	-	-
M Jackson	-	-	-	-
T Pethick	-	-	-	-

Options held by J Ivers under the Save As You Earn scheme vested and were exercised in July 2012. The exercise price was 19.72 pence per share, with all new shares then being immediately acquired by Acromas BidCo Limited (the immediate parent company) at 110 pence per share. The options held by Martyn Ellis under the Save As You Earn scheme will vest in July 2013, the exercise price being 43.60 pence per share.

### Country of incorporation

The Company is incorporated in Great Britain and registered in England and Wales.

**Charitable and political donations**

No charitable or political donations were made during the year (2012 £nil)

**Company Secretary**

John Davies resigned as Company Secretary on 17<sup>th</sup> August 2012 and was replaced by Andrew Paul Stringer from the same date

**Auditors**

Ernst & Young LLP have expressed their willingness to continue in office as auditors

**Principal risks and uncertainties**

The principal risk for the Company derives from possible impairments to the fair value of its investments. These investments consist of (indirect) ownership of major trading subsidiaries in the healthcare and homecare sectors within the Acromas group of companies, possible impairments could arise from various commercial factors, each of which are more fully explained within the financial statements of the respective subsidiaries

**Directors' responsibilities to the auditors regarding the financial statements**

Each person who is a director at the date of approval of this directors' report confirms that

- so far as the director is aware, there is no relevant audit information of which the Company's auditors are unaware, and
- each director has taken all the steps that he or she ought to have taken as a director to make himself or herself aware of any relevant audit information and to establish that the Company's auditors are aware of that information

## Directors' responsibilities statement

The directors are responsible for preparing the directors' report and the financial statements in accordance with applicable law and regulations

Company law requires the directors to prepare financial statements for each financial period. Under that law the directors have elected to prepare the financial statements in accordance with UK Generally Accepted Accounting Principles ("UK GAAP"). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of the profit or loss of the Company for that period.

In preparing these financial statements, the directors are required to

- select suitable accounting policies and then apply them consistently,
- make judgements and accounting estimates that are reasonable and prudent,
- state whether they have been prepared in accordance with UK Generally Accepted Accounting Principles, subject to any material departures disclosed and explained in the financial statements,
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by the Board on 24 July 2013 and signed on its behalf by



Martyn Ellis  
Director  
Nestor Healthcare Group Limited

Registered number 1992981

## **Independent auditors' report to the shareholders of Nestor Healthcare Group Limited**

We have audited the financial statements of Nestor Healthcare Group Limited for the year ended 31 January 2013 which comprise the Profit and Loss Account, the Balance Sheet, the Statement of Total Recognised Gains and Losses, the Reconciliation of Movements in Shareholders' Funds and the related notes 1 to 14. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

### **Respective responsibilities of directors and auditor**

As explained more fully in the Directors' Responsibilities Statement set out on page 4, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view. Our responsibility is to audit and express an opinion on the financial statements in accordance with applicable law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practices Board's Ethical Standards for Auditors.

### **Scope of the audit of the financial statements**

An audit involves obtaining evidence about the amounts and disclosures in the financial statements sufficient to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or error. This includes an assessment of whether the accounting policies are appropriate to the company's circumstances and have been consistently applied and adequately disclosed, the reasonableness of significant accounting estimates made by the directors, and the overall presentation of the financial statements. In addition, we read all the financial and non-financial information in the Directors' report and financial statements to identify material inconsistencies with the audited financial statements. If we become aware of any apparent material misstatements or inconsistencies we consider the implications for our report.

### **Opinion on financial statements**

In our opinion the financial statements

- ▶ give a true and fair view of the state of the company's affairs as at 31 January 2013 and of its loss for the year then ended,
- ▶ have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice, and
- ▶ have been prepared in accordance with the requirements of the Companies Act 2006


**Opinion on other matter prescribed by the Companies Act 2006**


In our opinion the information given in the Directors' Report for the financial period for which the financial statements are prepared is consistent with the financial statements

**Matters on which we are required to report by exception**

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion

- ▶ adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us, or
- ▶ the financial statements are not in agreement with the accounting records and returns, or
- ▶ certain disclosures of directors' remuneration specified by law are not made, or
- ▶ we have not received all the information and explanations we require for our audit

  
Benjamin Gregory (Senior statutory auditor)  
for and on behalf of Ernst & Young LLP, Statutory Auditor  
London



2013

## Profit and loss account

for the year ended 31st January 2013

	Notes	Year to 31 01 13 £'000	13 months to 31 01 12 £'000
Administrative expenses		(5)	(4 048)
Operating loss	3	(5)	(4 048)
Interest payable and similar charges	4	(6)	(92)
Loss before taxation		(11)	(4 140)
Taxation - tax (charge)/credit	5	(80)	595
Loss for the period		(91)	(3 545)

Comparative numbers are shown for the 13 months ended 31st January 2012  
All results have been derived from continuing operations

The notes on pages 10 to 13 form an integral part of these financial statements



## Statement of total recognised gains and losses

for the year ended 31st January 2013

	Notes	Year to 31 01 13 £'000	13 months to 31 01 12 £'000
Loss for the period	10	(91)	(3 545)
<b>Total recognised losses relating to the year</b>		<b>(91)</b>	<b>(3 545)</b>

## Reconciliation of movements in shareholder's funds

for the year ended 31st January 2013

	Notes	Year to 31 01 13 £'000	13 months to 31 01 12 £'000
Total recognised gains and losses relating to the year	10	(91)	(3,545)
Share capital issued	9	112	571
Share premium issued	10	112	473
Increase in share payment reserve	10	90	910
Shareholder's funds brought forward		134 265	135 856
<b>Shareholder's funds carried forward</b>		<b>134,488</b>	<b>134 265</b>


The notes on pages 10 to 13 form an integral part of these financial statements

**Balance sheet**  
as at 31st January 2013

	Notes	31 01 2013 £'000	31 01 2012 £'000
<b>Fixed assets</b>			
Investments	6	112,661	112 571
<b>Fixed assets</b>		<b>112,661</b>	<b>112 571</b>
<b>Current assets</b>			
Trade and other debtors	7	21,798	21 682
Cash at bank and in hand		30	13
<b>Current assets</b>		<b>21,828</b>	<b>21,695</b>
<b>Creditors</b>			
Amounts falling due within one year	8	(1)	(1)
<b>Creditors</b>		<b>(1)</b>	<b>(1)</b>
<b>Net current assets</b>		<b>21,827</b>	<b>21 694</b>
<b>Total assets less current liabilities</b>		<b>134,488</b>	<b>134 265</b>
<b>Net assets</b>		<b>134,488</b>	<b>134 265</b>
<b>Capital and reserves</b>			
Called up share capital	9	11,977	11 865
Share premium account	10	72,056	71 944
Share payment reserve	10	3,399	3 309
Profit and loss account	10	47,056	47 147
<b>Equity shareholder's funds</b>		<b>134,488</b>	<b>134 265</b>

The notes on pages 10 to 13 form an integral part of these financial statements

The financial statements on pages 7 to 13 were approved by the Board on 24 July 2013



MA Ellis

Nestor Healthcare Group Limited  
Company registration number 1992981

## Notes to the financial statements

for the year ended 31st January 2013

### 1 Basis of preparation

These financial statements have been prepared under the historical cost convention and in accordance with applicable accounting policies as defined in the Companies Act 2006 s 464

In the 13 month period ended 31st January 2012 the financial statements were prepared in accordance with those International Financial Reporting Standards (IFRS) which had been adopted by the European Commission and endorsed for use in the EU (collectively "Adopted IFRS"). However as the Company's ultimate parent company, Acromas Holdings Limited, prepares its financial statements under UK GAAP, the directors of the Company have concluded therefore that henceforth the financial statements should be prepared similarly. These financial statements for the year ended 31st January 2013 have therefore been prepared in accordance with UK GAAP whilst the comparative statements for the 13 month period ended 31st January 2012 have been restated

Restatement of the comparative statements for the 13 month period ended 31st January 2012 has not occasioned any restatement of the reported amounts of assets and liabilities at the date of the accounts or the reported amounts of income and expenses during the reported period

The Company has taken advantage of the exemption available to it under FRS 8 not to disclose related party transactions

The financial statements have been prepared in pounds sterling which is the functional currency of the Company

The principal accounting policies are set out below

#### Estimates and judgements

The preparation of accounts in accordance with accounting standards requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the accounts and the reported amounts of income and expenses during the reported period. These estimates are based on historical experience and various other assumptions that management and directors believe are reasonable under the circumstances, the results of which form the basis for making judgements about the carrying value of assets and liabilities that are not readily apparent from other sources. Areas comprising critical judgements that may significantly affect the Company's earnings and financial position are the valuation of investments and of income taxes including tax enquiries and share-based payments, all of which are discussed in the respective notes

### 2 Accounting policies

#### Basis of consolidation and accounting reference date

The accounting reference date of the Company is 31st January. These financial statements are accordingly presented for the year ended 31st January 2013, whereas comparative figures for the prior period are presented for the 13 months to 31st January 2012, and may not therefore be comparable. The accounting reference date was changed in the previous period to align with that of Acromas Holdings Limited, which has been the ultimate holding company since 1st February 2011

The Company has taken advantage of the exemption from preparing consolidated financial statements as at 31st January 2013 it was a wholly owned subsidiary of its ultimate parent, Acromas Holdings Limited

#### Interest receivable and payable

Borrowing costs are recognised in the profit and loss account in the period in which they are incurred

Interest is accrued on a time basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the asset's net carrying amount. Dividend income from investments is recognised when shareholders' rights to receive payment have been established

#### Deferred taxation

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more or right to pay less or to receive more tax. Deferred tax is measured on a non-discounted basis at the tax rates that are expected to apply in the years in which timing differences reverse, based on tax rates and laws enacted or substantively enacted at the balance sheet date. Deferred tax assets are recognised only to the extent that the Directors consider it is more likely than not that there will be suitable taxable profits from which the underlying timing differences can be deducted

#### Investments

Investments in subsidiary undertakings are held at original cost less any provision for impairment

#### Cash at bank and in hand

Cash at bank and in hand comprise balances at banks together with balances of cash in hand

#### Share schemes and share-based payments

The Company has issued equity settled share based payments to certain employees of a subsidiary company under the terms of various share and share option schemes, including Save As You Earn share option schemes

These equity settled share-based payments are measured at fair value as at the date of grant. The fair value so determined at the grant date has been expensed on a straight line basis over the vesting period in the financial statements of the subsidiary company

The liability in respect of these shares is accounted for as a capital contribution made to the subsidiary company by the Company, and as such is recognised as an increase in investments in the balance sheet of the Company

#### Cash flow statements

The Company has taken advantage of the exemption available to it under FRS 1 not to prepare a cash flow statement

## Notes to the financial statements

for the year ended 31st January 2013

### 3 Operating loss

Operating loss is defined as loss before interest receivable and payable

The audit fee for the Company of £2,000 for the audit of the financial statements (period to 31st January 2012: £500) was borne by another group company

Amounts paid to Ernst & Young LLP by the Company in respect of non-audit services for the period ended 31 January 2013 were £nil (2012: £nil)

There were no staff costs associated with the Company in the current or prior year

### 4 Interest payable

	Year to 31 01 13 £000	13 months to 31 01 12 £000
Interest payable and similar charges		
Interest payable on bank overdrafts	(6)	(92)
<b>Total interest payable and similar charges</b>	<b>(6)</b>	<b>(92)</b>

### 5 Taxation

	Year to 31 01 13 £000	13 months to 31 01 12 £000
UK corporation tax at 24.33% (2012: 26.45%)	3	366
(Under)/over provision in previous years: current tax	(82)	227
<b>Current tax (charge)/credit</b>	<b>(79)</b>	<b>593</b>
Origination and reversal of temporary differences		2
Deferred tax adjustment in respect of prior periods		
Effect of tax rate change on opening deferred tax balance	(1)	
<b>Deferred tax (charge)/credit</b>	<b>(1)</b>	<b>2</b>
<b>Tax (charge)/credit for the period</b>	<b>(80)</b>	<b>595</b>

	Year to 31 01 13 £000	13 months to 31 01 12 £000
Loss at the average standard rate of corporation tax at 24.33% (2012: 26.45%)	3	1,094
Items not deductible		(726)
Tax relating to previous years	(82)	227
<b>Current tax (charge)/credit for the period</b>	<b>(79)</b>	<b>595</b>

The Finance Act 2012 reduced the main rate of corporation tax from 26% to 24% with effect from 1st April 2012 and further reduced it from 24% to 23% with effect from 1st April 2013. As this reduction was substantively enacted on 3rd July 2012, the deferred tax balance at 31st January 2013 has been stated at 23%.

The Chancellor has announced that he intends to further reduce the main rate of Corporation Tax to 21% with effect from 1st April 2014 and to 20% with effect from 1st April 2015. The directors estimate that the effect of this proposed rate change will not have a material impact on the Company's deferred tax balance.

### 6 Investments

	Investment in subsidiaries 31 01 2013 £000
At 1st February 2012	112,571
Capital contributions for share-based payments	90
<b>At 31st January 2013</b>	<b>112,661</b>
At 31st January 2012	112,571

Investments comprise investments in subsidiary undertakings which are held at cost less any provision for impairment.

Except where stated, the following subsidiary companies are wholly-owned including 100% voting rights, operate in the UK and are registered in England and Wales:

Principal undertakings Undertaking	Business
Nestor Primcare Services Limited <sup>1</sup>	UK healthcare services in primary and social care
Primcare Oral Health Services Limited <sup>1</sup>	Dental health services
Helenus Limited	Intermediate holding company

<sup>1</sup> The interest of Nestor Healthcare Group Limited is held through intermediate holding companies

The directors consider that to give full particulars of all subsidiary undertakings would lead to a statement of excessive length. A full list of subsidiary undertakings is available at the Company's registered office.

## Notes to the financial statements

for the year ended 31st January 2013

### 7 Trade and other debtors

	Year to 31.01.13 £000	13 months to 31.01.12 £000
Amounts owed by Group companies	21,796	21,680
Recognised deferred tax assets	2	2
Trade and other debtors due within one year	21,798	21,682

The Company has no unprovided deferred tax (2012 £28,000 asset in relation to losses and other deductions)

### 8 Creditors

	Year to 31.01.13 £000	13 months to 31.01.12 £000
Accruals and deferred income	1	1
Total creditors	1	1

### 9 Share capital

	31.01.2013 Number	31.01.2013 £000	31.01.2012 Number	31.01.2012 £000
Authorised				
Ordinary shares of 10p each	200,000,000	20,000	200,000,000	20,000
Allotted issued and fully paid				
Ordinary shares of 10p each				
At the beginning of the period	118,651,634	11,865	112,941,293	11,294
Increase in the period	1,119,259	112	5,710,241	571
At 31st January	119,770,793	11,977	118,651,534	11,865

The ordinary shares in issue are considered by the Company to be capital in nature. The Company is not subject to any externally imposed capital requirements.

New ordinary shares were issued in the year to satisfy exercises of options under the Company's Save As You Earn sharesave scheme.

### 10 Share premium account and reserves

	Share premium account £000	Share payment reserve £000	Retained earnings £000
At 1st February 2012	71,944	3,309	47,147
Share-based payments (note 12)		90	-
Issue of shares	112		-
Loss for the year			(91)
At 31st January 2013	72,056	3,399	47,056
At 31st January 2012	71,944	3,309	47,147

Retained earnings of the Company as at 31st January 2013 comprise £4,056,000 that is considered to be distributable (2012 £4,147,000) and £43,000,000 that is considered to be non-distributable (2012 £43,000,000). Non-distributable retained earnings represents dividends received from a subsidiary company that could not be classed as qualifying consideration.

All categories of reserve disclosed above are considered by the Company to be capital in nature. The Company is not subject to any externally imposed capital requirements.

### 11 Employees and directors

The Company had no employees (2012 nil) during the period.

S M Howard and T M Pethick were remunerated by Saga Group Limited, a fellow subsidiary of the ultimate holding company Acromas Holdings Limited. They did not receive any emoluments during the period in respect of their services as directors of the Company (period to 31st January 2012: £nil) and it would not be practicable to apportion the emoluments between their services as directors of the Company and services as directors of other group companies. The Company has not been recharged any amount for the emoluments of these directors (period to 31st January 2012: £nil).

J Ivers and M A Ellis were remunerated by Nestor Primecare Services Limited, a fellow subsidiary of the ultimate holding company Acromas Holdings Limited. They did not receive any emoluments during the period in respect of their services as directors of the Company (period to 31st January 2012: £nil) and it would not be practicable to apportion the emoluments between their services as directors of the Company and services as directors of other group companies. The Company has not been recharged any amount for the emoluments of these directors (period to 31st January 2012: £nil).

### 12 Share option schemes

The following table sets out options in issue under the various Company schemes at the beginning and end of the period and movements during the period. Share options in issue expire after a certain time and exercise dates vary. Exercise rights are subject to the rules of the schemes and share options in issue are not normally exercisable until the expiry of a period of at least three years. In addition, achievement of performance targets is normally required in all schemes except the SAYE Scheme.

All options outstanding under the Share Option Plan 2002 vested on 1st February 2011 as a consequence of the acquisition of the Company by Saga Group Limited. All options outstanding under CSOP 1996 and ESOP 1996 Share Option Plan 2002 lapsed on that same date as a result of the option exercise price being higher than the acquisition price payable by Saga Group Limited.

1,119,259 options (period to 31st January 2012: 1,683,232) were exercised during the period at an average exercise price of 20.04p (2012: 38.11p). The weighted average share price for share options exercised during the period was 110.00p (2012: 109.98p) equal to the price per share paid by Saga Group Limited for all shares in issue and to be issued on 1st February 2011.

The number of options that had vested and were exercisable at 31st January 2013 was nil (31st January 2012: nil).

The average exercise price of grants that lapsed in the period to 31st January 2013 was 41.79p (2012: 76.12p).

Movements in the period to 31st January 2013 were as follows:

## Notes to the financial statements

for the year ended 31st January 2013

### 12 Share option schemes (continued)

Date of issue	Adjusted option price pence	In issue 1st Feb 2012	Granted in the period	Exercised in the period	Lapsed in the period	In issue 31st Jan 2013
<b>Savings Related Share Option Scheme</b>						
May 2007	140.04	1,403			(1,403)	-
June 2008	41.40	31,934		(3,632)		28,302
April 2009	19.72	1,203,551		(1,103,772)	(10,897)	88,882
April 2010	43.60	544,564	-	(11,855)	(56,703)	476,006
		1,781,452		(1,119,259)	(69,003)	593,190
<b>Total</b>		1,781,452		(1,119,259)	(69,003)	593,190

Movements in the period to 31st January 2012 were as follows

Date of issue	Adjusted option price pence	In issue 1st Jan 2011	Granted in the period	Exercised in the period	Lapsed in the period	In issue 31st Jan 2012
<b>Company Share Option Plan 1996</b>						
March 2001	509.74	4,104			(4,104)	-
		4,104			(4,104)	-
<b>Employee Share Option Scheme 1996</b>						
March 2001	509.74	10,897			(10,897)	-
		10,897			(10,897)	-
<b>Share Option Plan 2002</b>						
April 2009	25.67	746,398	-	(746,398)		-
April 2010	54.50	615,988		(615,988)		-
August 2010	78.94	21,264		(21,264)		-
		1,383,650		(1,383,650)		-
<b>Savings Related Share Option Scheme</b>						
May 2007	140.04	40,929	-	-	(39,526)	1,403
June 2008	41.40	215,181	-	(163,290)	(19,957)	31,934
April 2009	19.72	1,423,422	-	(124,075)	(95,796)	1,203,551
April 2010	43.60	647,054	-	(12,217)	(90,273)	544,564
		2,326,586	-	(299,582)	(245,552)	1,781,452
<b>Total</b>		3,725,237	-	(1,683,232)	(260,553)	1,781,452

The share-based payment charge calculated for the year ended 31st January 2013 is £90,000 (period to 31st January 2012: £911,000). The elements of this charge analysed by share-based transaction are as follows:

	Fair value of one award £	Total fair value charge Year to 31 01 13 £000	Total fair value charge 13 months to 31 01 12 £000
Savings Related Share Option Scheme - 2007 awards	0.91 and 1.05	2	5
Savings Related Share Option Scheme - 2008 awards	0.20 and 0.21	1	8
Savings Related Share Option Scheme - 2009 awards	0.13 and 0.13	34	83
Savings Related Share Option Scheme - 2010 awards	0.24 and 0.24	53	58
Performance Share Plan - 2008 awards	0.39 and 0.26	-	58
Performance Share Plan - 2009 award	0.22	-	155
Performance Share Plan - 2010 awards	0.43 and 0.72	-	386
Share Option Plan 2002 - 2009 award	0.11	-	36
Share Option Plan 2002 - 2010 awards	0.25 and 0.43	-	122
<b>Total charge</b>		<b>90</b>	<b>911</b>

This charge, which has been expensed in the financial statements of another group company, forms the basis of the credit to the share payment reserve of the Company (see note 10).

### 13 Immediate and ultimate parent undertakings

During the year ended 31st January 2013 Saga Group Limited sold its shareholding in the Company to Acromas Bid Co Limited, another company within the Acromas group of companies. Acromas Bid Co Limited, a company incorporated in Great Britain and registered in England and Wales, is accordingly now the immediate parent of the Company.

The financial statements of the Company have been consolidated in the group financial statements of Acromas Bid Co Limited (a parent undertaking) and Acromas Holdings Limited (the ultimate parent undertaking), both of which are registered in England with registered office Enbrook Park, Sandgate, Folkestone, Kent CT20 3SE.

Acromas Bid Co Limited is the parent company of the smallest group of which the Company is a member and for which group financial statements are prepared.

### 14 Ultimate controlling party

The directors consider the controlling party to be funds advised by Charterhouse General Partners, CVC Capital Partners and Permira Advisers acting in concert.